|
| |
BioPortfolio's Approved Drugs DatabaseRegranexBecaplerminDownload PDF containing detailed information.
Press Releases About Regranex:
|
 |
| Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications |
7th May, 2009 |
Cardium Therapeutics |
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced significant new formulation enhancements for its
|
| Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers |
6th May, 2009 |
Cardium Therapeutics |
SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase
|
| ETHICON, INC. Announces Revised Label For REGRANEX(R) (becaplermin) Gel 0.01% |
6th June, 2008 |
ETHICON, INC. |
SOMERVILLE, N.J., June 6 /PRNewswire/ -- ETHICON, INC. today announces
revised labeling for REGRANEX Gel, a topical formulation of recombinant human
platelet-derived growth factor indicated as an
|
This page has been viewed 26 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Regranex across BioPortfolio, or for Regranex Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|